Comparison of bicyclol therapy for patients with genotype B and C of hepatitis B virus
Ruan, B.; Wang, J.-w.; Bai, X.-l.
Zhonghua Shi Yan he Lin Chuang Bing du Xue Za Zhi 21(4): 366-368
2007
ISSN/ISBN: 1003-9279 PMID: 18322605 Document Number: 606525
To compare the efficacy of bicyclol tablets on patients infected with hepatitis B virus between genotype B and C. 70 patients with chronic viral hepatitis B were selected. The patients divide into two groups: HBV genotypes B (26 cases) and HBV genotypes C (other 44 cases). All patients received bicyclol tablets orally 150 mg daily (50mg, tid, po) for 24 weeks. The efficacy were observed after 12 weeks and 24 weeks. After treatment for 24 weeks, the serum aminotransferase were decreased obviously, and HBV DNA levels turn to be negative with 19.2 percent (genotype B group) and 15.9 percent (genotype C group), respectively. The difference was not statistically significant between HBV genotype B and C. Bicyclol not only has hepatoprotective activity but also inhibited virus replication in patients infected with HBV. The difference of the response to bicyclol therapy between HBV genotypes B and C was not statistically significant.